Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
CSL, GSK and Sanofi
Sanofi, GSK, CSL tapped to expand US bird flu vaccine supply
GSK , Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a health official said on Friday during a press briefing.
BARDA doles out $72M to Sanofi, GSK and CSL for bird flu vaccine supply
The Center for Biomedical Advanced Research and Development Authority (BARDA) is giving $72 million to three drugmakers to help fortify the US supply of bird flu vaccine ahead of 2025. The funding was disclosed by the Administration for Strategic Preparedness and Response,
GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report
The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and Australian firm CSL Limited (OTC:CSLLY) to more than double the U.S. supply of bird flu vaccines.
GSK, Sanofi, CSL nab $72M in BARDA funding to boost bird flu vaccine supply
CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the country’s supply of bird flu vaccines. | CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.
GSK, Sanofi, CSL said to win $72M U.S. bird flu vaccine contract (update)
Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission. Read more here.
3d
Sanofi Healthcare Bidders Revising Offers Over Talc Concerns
Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...
3d
on MSN
Recordati buys rights to rare immune disorder drug from Sanofi for $825 million
(Reuters) -Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat ...
FiercePharma
3d
In sustained rare disease push, Recordati lays out $825M upfront to acquire Sanofi's CAD drug Enjaymo
As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...
3d
on MSN
Sanofi inks $1B deal to sell autoimmune disorder therapy
French pharma giant Sanofi (NASDAQ:SNY) has agreed to sell global rights linked to Enjaymo, an FDA-approved treatment for an ...
6d
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as ...
3d
Sanofi Sells Global Rights To Rare Autoimmune Drug Enjaymo For $825M Upfront To Italian Firm Recordati
Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...
BioSpace
3d
Sanofi Offloads Rare Autoimmune Drug to Recordati in Potential $1B Deal
Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...
BioPharma Dive
3d
Sanofi’s rare disease drug finds yet another home
Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed to Recordati as part of a deal announced Friday.
PMLiVE
5d
Sanofi/Regeneron’s Dupixent approved by FDA to treat uncontrolled COPD
Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Recordati
Enjaymo
GSK
CSL
Food and Drug Administration
Feedback